Virtual Seminar: Dissecting Toxicities of Immune Checkpoint Inhibitors
Douglas Johnson, M.D., MSCI
Associate Professor of Medicine
Clinical Director, Melanoma Program
Ingram Cancer Center
Vanderbilt University
Virtual Pioneers in Biomedical Research Seminar: Dissecting Toxicities of Immune Checkpoint Inhibitors
Nov. 19, 2021
11:00 a.m. to 12:00 p.m.
Archived video
About this Seminar
Anti-PD-1 therapy has dramatically altered cancer treatments, but many unanswered questions remain. First, the need for more accurate biomarkers to provide clues to the pathogenesis of response and resistance, and to more accurately assign patients to effective treatment remains a key unmet need. Tumor cell expression of MHC class II and tumor mutational burden are two potential markers of response. Second, patients treated with anti-PD-1, especially when used in combination, frequently experience severe immune-related toxicities. Identifying patients at risk, clinically phenotyping clinical events, and determine effective treatment strategies remain unmet needs. In this presentation, Dr. Johnson will discuss his lab's work in identifying anti-PD-1 biomarkers, particularly focusing on MHC-II and tumor mutational burden, and in characterizing anti-PD-1 toxicities.
Additional Details
This is a free event hosted by the Fralin Biomedical Research Institute and co-sponsored by the institute's Cancer Research Group. The Pioneers in Biomedical Research Seminar Series, which runs annually from September to May, has featured leading biomedical researchers from throughout the country since the program began in 2012. The lectures are also open to all members of the Virginia Tech community including graduate students, undergraduates, faculty, and staff, as well as the public.
You May Also Be Interested In...
-
Home ItemCANCELLED: In Person Seminar: A Novel Metabolic-Epigenetic Axis in Vascular Remodeling Processes , home
CANCELLED: Feb. 3, 2023, 11 a.m. | Sébastien Bonnet, Ph.D., Professor, Department of Medicine, Director, Canadian Research Chair in Translational Research in Pulmonary and Vascular Diseases, Director, Pulmonary Hypertension Research Group, University of Laval | Pioneers in Biomedical Research Seminar Series | Co-Sponsored by the Fralin Biomedical Research Institute Center for Vascular and Heart Research
-
Home ItemIn Person Lecture: Achieving Cancer Health Equity – A Model of Integrating Research, Advocacy and Policy for Colorectal Cancer , home
Feb. 3, 2023, 1 p.m. | Chyke Doubeni, M.B.B.S., M.P.H., Professor and Chief Health Equity Officer, Wexner Medical Center, The Ohio State University | Timothy A. Johnson Medical Scholar Lecture Series
-
Home ItemSeminar: Integrated Bioelectronic Systems for Biomedical Research and Healthcare: Materials, Electronics, and Computing , home
Feb. 7, 2023, 12 p.m. | Wei Ouyang, Ph.D., Postdoctoral Fellow, Querrey Simpson Institute for Bioelectronics, Northwestern University | Seminar
-
Home ItemSeminar: Molecular Targets of Prenatal Alcohol Exposure During Early Brain Development , home
Feb. 8, 2023, 2 p.m. | Karen Boschen, Ph.D., Postdoctoral Research Associate, Bowles Center for Alcohol Studies, University of North Carolina School of Medicine | Seminar
-
Home ItemIn Person Lecture: Developmental Cognitive Neuroscience in the Era of Big Data , home
Feb. 9, 2023, 5:30 p.m. (Reception at 5 p.m.) | Damien Fair, PA-C, Ph.D., Professor, Institute of Child Development, Department of Pediatrics, College of Education and Human Development, University of Minnesota Medical School | Maury Strauss Distinguished Public Lecture
-
Home ItemIn Person Seminar: Pathogenic Mechanisms and Novel Therapies for Immune Neoplasms , home
Feb. 10, 2023, 11 a.m. | Ari Melnick, M.D., Gebroe Family Professor of Hematology/Oncology, and Director, Sackler Center for Biomedical and Physical Sciences, Weill Medical College, Cornell University | Pioneers in Biomedical Research Seminar Series | Co-Sponsored by the Fralin Biomedical Research Institute Cancer Research Group